Amgen Urges Justices To Leave Enbrel Patent Ruling Alone
Law360 (April 12, 2021, 7:57 PM EDT) -- Amgen Inc. unit Immunex said Monday that there's no need for the U.S. Supreme Court to review a decision finding the biopharmaceutical company didn't patent the same invention twice for its blockbuster autoimmune drug Enbrel, saying the ruling was "case-specific" and correct.
In a brief opposing Novartis AG subsidiary Sandoz Inc.'s petition for certiorari, Immunex Corp. said Sandoz had "simply lost on its own facts" in trying to prove that Immunex's deal to exclusively license Enbrel through patents owned by Hoffmann-La Roche Inc., while itself owning earlier-expiring patents for the drug, constituted disallowed obviousness-type double-patenting.
In the split decision at issue,...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!